NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
NCT06259929
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
51
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
Abemaciclib 150 MG + Giredestrant 30 MG
Sponsor
Fondazione Oncotech